Big Pharma's Business Model Under Threat as Weight-Loss Prices Plummet

Big Pharma's business model is being disrupted by price wars in the weight-loss market. Novo Nordisk's Wegovy pill, a GLP-1 prescription, has seen its price drop from over $1,000/month for uninsured patients to $149 through cash-pay programs. This unprecedented drop in price is a significant shift in the pharmaceutical industry, challenging traditional business models.